Evidence map›Paper›PMID 40980906›Full record

ArticlemSphere2025

CRISPR adaptation in

F R Croteau, J Tran, A P Hynes

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

F R CroteauDepartment of Biochemistry and Biomedical sciences, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
J TranDepartment of Biochemistry and Biomedical sciences, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
A P HynesDepartment of Biochemistry and Biomedical sciences, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0002-7058-6006

Funding

Farncombe Family Chair in Phage BiologyNatural Sciences and Engineering Research Council of Canada 2018-05996
6 · The paper itself

Abstract

The CRISPR-Cas system is a bacterial adaptive immune system that protects against infection by phages: viruses that infect bacteria. To develop immunity, bacteria integrate spacers-fragments of the invading nucleic acids-into their CRISPR array to serve as the basis for sequence-targeted DNA cleavage. However, upon infection, a phage quickly takes over the metabolism of the bacterium, leaving little time for the bacterium to acquire new spacers, transcribe them, and use them to cut the invading DNA. To develop CRISPR immunity, bacteria must be safely exposed to phage DNA. Phage infection releases environmental DNA (eDNA) which could be involved in the development of CRISPR immunity. Using

Indexed as

BacteriophagesClustered Regularly Interspaced Short Palindromic RepeatsCRISPR-Cas SystemsDNA, ViralStreptococcus PhagesStreptococcus thermophilusDNA, Viraladaptive immunitybacteriophageCRISPR-CaseDNAenvironmental DNAnatural competencephage resistance

Identifiers

PMID40980906
PMCPMC12570759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.